Enanta Pharmaceuticals (ENTA) risk factors
Item 1A of every Enanta Pharmaceuticals Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors56 risks1 new1 dropped5 reworded
Refreshed competitive landscapes for RSV and AD by adding new competitor drug approvals and pipeline updates. Disclosed a $74.8 million public offering of common stock completed in October 2025. Added strict warnings regarding third-party healthcare reimbursement limitations and pricing pressures.
Filed Nov 19, 2025 - FY2024 10-K risk factors56 risks
Enanta requires substantial additional funding to advance its preclinical and clinical pipelines in viral and inflammatory diseases. Its key revenue source depends entirely on AbbVie commercializing the MAVYRET/MAVIRET hepatitis C regimen. The company faces intense competition across therapeutic areas like RSV, CSU, AD, COVID-19, and HBV from major pharmaceutical firms.
Filed Nov 27, 2024